Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia
- Status
- COMPLETED
- Phase
- PHASE1
VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning
- Status
- COMPLETED
- Phase
- PHASE2
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation
- Status
- TERMINATED
- Phase
- PHASE2
Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
- Status
- COMPLETED
- Phase
- PHASE3
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
- Status
- TERMINATED
- Phase
- PHASE3
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2